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Stage I Non-small Cell Lung Cancer (NSCLC) in Patients
Aged 75 Years and Older
Does Age Determine Survival After Radical Treatment?
David A. Palma, MD,*†‡ Scott Tyldesley, MD,* Finbarr Sheehan, MD,* Islam G. Mohamed, MD,§
Sally Smith, MD, Elaine Wai, MD, Nevin Murray, MD,¶ and Suresh Senan, MRCP, FRCR, PhD†
Introduction: Curative treatment of stage I non-small cell lung
cancer (NSCLC) in elderly patients represents a therapeutic chal-
lenge. Data examining outcomes for the elderly after radical radio-
therapy (RT) or surgery in the same geographic population are
limited.
Methods: Using prospective databases from British Columbia,
patients with stage I NSCLC treated curatively with either surgery or
RT between 2000 and 2006 were identified. Kaplan-Meier, Cox
regression, and competing risk analyses were used to assess overall
survival (OS) and disease-specific survival in the elderly, and the
relationship between age and survival outcomes.
Results: Of a total of 558 patients with stage I disease, 310 (56%)
received surgery and 248 (44%) received RT. Elderly patients (age
75 years) were less likely to undergo resection than their younger
counterparts (43% versus 72%, p  0.0001). Actuarial OS after
surgery for elderly patients was 87% at 2 years and 69% at 5 years.
On multivariate analysis, OS after surgery was dependent on tumor
stage (p  0.034) and performance status (p  0.03), but not age
(p  0.87). After RT, actuarial OS for elderly patients was 53% at
2 years and 23% at 5 years. On multivariate analysis, age did not
predict for OS after RT (p  0.43), whereas tumor stage (p 
0.033), sex (p  0.044), and dose (p  0.01) were significant
predictors.
Conclusions: Survival after radical treatment for stage I NSCLC is
dependent on factors such as tumor stage, performance status, sex,
and RT dose, but not age. Elderly patients who are sufficiently fit
should not be considered ineligible for radical treatment based on
age alone.
Key Words: Geriatric oncology, Elderly, Lung cancer, Surgery,
Radiotherapy.
(J Thorac Oncol. 2010;5: 818–824)
Lung cancer is increasingly a disease of older patients. Themedian age of diagnosis is 70 years, and one in three
patients is aged 75 years or older.1 Although lung cancer
incidence rates are stable or falling in many countries, this
has been offset by the expansion of the elderly demographic,
resulting in an overall increase in the number of elderly
patients with lung cancer.1–3 For example, in Canada, the
age-standardized incidence rates for lung cancer have de-
creased in men and stabilized in women between 2000 and
2005,4 but in the same time period, the number of elderly
people (age75 years) diagnosed with lung cancer increased
approximately 20%.5
Elderly patients are less likely to receive protocol-
specified treatment, often due to concerns about comorbidity,
frailty, or efficacy.1,6,7 Almost 70% of elderly lung cancer
patients have significant comorbidities, compared with about
50% of younger patients.8 Physiologic changes that occur
with aging may alter the efficacy or toxicity of treatment.9
Postoperative risks are higher in elderly patients, particularly
those with impaired performance status.3,10 Nonsurgical op-
tions, such as conventional external beam radiotherapy (RT),
have historically demonstrated inferior outcomes when com-
pared with surgery,11,12 with only small improvements in
median survival compared with no treatment.13 This has led
to instances of medically inoperable elderly patients being
deferred treatment until development of symptoms.12
Elderly patients are less often subjects of clinical tri-
als,14,15 leading to more uncertainty about optimal manage-
ment and a greater reliance on other types of comparative
effectiveness studies. Several studies have examined out-
comes for elderly patients with stage I non-small cell lung
cancer (NSCLC) after either surgery or RT, but no large or
recent studies have reported outcomes for both treatments,
with curative intent, from the same baseline population. This
is an important distinction, because surgical and radiothera-
peutic outcomes depend highly on patient selection. Reports
on only one of these two treatment options may give an
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incomplete picture of outcomes for elderly patients. The aims
of our study were to assess survival outcomes for elderly
patients with stage I lung cancer treated with radical intent
and to determine the impact of age on posttreatment survival.
METHODS
Data Sources
The majority of cancer care in British Columbia (BC),
a province in excess of 4 million people, is provided by the
BC Cancer Agency (BCCA). Treatment policy for lung
cancer in the province is generated by the Lung Tumor
Group, and the treatment guidelines are published online
(www.bccancer.bc.ca). The BC Cancer Registry captures all
diagnoses of cancer in the province of BC (case ascertain-
ment rate of 90% between 2000 and 200516), along with
demographic data, histology, and vital statistics. Staging data
is not captured. The BCCA maintains a separate database, the
oncology reporting system, which captures more detailed
information on all patients referred to the BCCA, including
clinical and pathologic stage, RT information, surgical pro-
cedures, and Eastern Cooperative Oncology Group (ECOG)
performance status. Data on specific staging investigations
are not included. The BCCA is the only provider of RT in the
province, therefore any patient receiving RT in BC (or seek-
ing a consultation for RT) at any time is included in this
database. Information on the cause and date of death is
captured by automatic reporting of death certificates to the
BC Cancer Registry. The last complete death update of the
registry was December 31, 2007, and patients who were alive
with no further follow-up after this date were censored as of
that date. Institutional ethics review board approval was
obtained before initiation of the study.
Both databases were queried in March 2009 for patients
with NSCLC diagnosed between January 1, 2000, and De-
cember 31, 2006. A total of 14,338 patients with NSCLC any
stage were diagnosed in the BC population during this time
period, of which 9388 were referred to the BCCA.
Patients were identified at first clinical and/or patho-
logic diagnosis of T1/T2 N0/X M0/X NSCLC, based on the
1997 American Joint Committee on Cancer definition. Pa-
tients with both clinical and surgical staging were only
included if they were stage I by both methods; therefore, all
surgical patients can be considered as pathologically T-
staged. Patients were excluded if there was a prior history of
cancer, other than nonmelanoma skin cancer, in the 5 years
before diagnosis; if the diagnosis was made postmortem or on
the date of death; or with a diagnosis of synchronous lung
cancers (defined as two separate diagnoses of lung cancer
within 6 months). Surgical patients were excluded if referred
to the BCCA more than 3 months after surgery or because of
recurrence. The databases were assessed for uncommon clin-
ical scenarios (e.g., patients coded as receiving chemotherapy
before or during local treatment), and those charts were
reviewed manually.
Patients were classified by primary radical local treat-
ment into two groups: surgery or RT. Nine patients who
received surgery plus adjuvant (n  8) or neoadjuvant (n 
1) RT were included in the surgery group. Patients were
classified as receiving radical RT if treatment intent was
coded as “radical” and they received a dose equivalent to 40
Gy in 20 fractions or higher. Because several fractionation
schemes were used with a variety of fraction sizes, RT doses
were normalized to 2 Gy per fraction equivalents using the
linear-quadratic formula.17
This resulted in a final sample size of 558 patients, 310
treated with surgery and 248 treated with RT. The RT cohort
includes all stage I patients treated with RT in BC. In this
study era, all these patients would have been routinely treated
with three-dimensional conformal RT because four-dimen-
sional computed tomography scanning was not available, and
elective nodal irradiation would not be standard. The surgical
cohort only includes patients referred to the BCCA. Using
data from previously administered surveys of family physi-
cians of nonreferred patients,18 we estimate that approxi-
mately 25% of stage I patients treated with surgery alone
during this time period are captured in this cohort. The
surgical patients included here either underwent surgery un-
der the care of a BCCA surgeon or were referred for any
BCCA service within the time periods specified above.
After data analysis, the accuracy of the final dataset was
assessed by a random review of the charts of 10% of patients.
The database was found to be highly accurate, with only
minor deviations found, none of which affected inclusion in
this study or outcomes.
Statistical Analysis
Baseline differences between the elderly (age 75
years) and nonelderly patients were compared using the t test,
Fisher’s exact test, or the 2 test, as appropriate. Kaplan-
Meier estimates of overall survival (OS) and disease-specific
survival (DSS) from date of diagnosis were generated, with
differences compared using the log-rank test. Cox regression
analysis was used to determine the factors associated with
survival outcome after the proportional hazards assumptions
were confirmed. Age was considered as a continuous variable
for multivariate analysis. To address the potential for com-
peting risks of death influencing the DSS analysis, these were
confirmed using a cumulative incidence methodology19 and
Fine and Gray’s regression analysis20 (results did not differ
and are not shown). All statistical tests were two-sided with
p  0.05 indicative of statistical significance, done using the
Statistical Package of Social Sciences (SPSS version 16.0,
Chicago, IL) or R (version 2.6.0).
RESULTS
The clinical characteristics of the 558 patients meeting
the inclusion criteria are shown in Table 1, stratified by age
and treatment modality. In the whole cohort, 310 patients
were treated with surgery and 248 with RT, of whom 211
(38%) were aged 75 or older. The median follow-up for all
patients was 2.4 years (range, 0.1–8.2 years). Older patients
were much less likely to undergo surgery than their younger
counterparts (72% of patients age 75 years versus 43% of
patients age 75 years, p  0.0001).
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Patients Treated with Surgery
Of the 310 patients treated with surgery, the median age
was 67 years (range, 20–86 years), and 63 patients (20%)
were aged 75 years or older. A comparison of the older and
younger age groups (shown in Table 1) revealed no signifi-
cant differences in baseline characteristics.
There were 75 deaths among the patients treated with
surgery. Estimated OS at 2 years was 87% and at 5 years was
69%. Figure 1 shows OS stratified by age category, with no
significant difference between elderly and younger patients
(p  0.38). In elderly patients, the OS rates were 88% at 2
years and 65% at 5 years. There were no changes in OS by era
of diagnosis (before 2003 versus 2003–2004 versus 2005 or
later) in the whole surgical cohort (p  0.32) or in the subset
of surgical patients who were elderly (p  0.61). On multi-
variate analysis (Table 2), age was not predictive of OS,
whereas tumor stage and ECOG performance status were
predictive of OS.
Of the 75 deaths, 50 were due to lung cancer. DSS was
91% at 2 years and 79% at 5 years. Figure 1B shows DSS by
age category, indicating a trend toward inferior DSS in the
patients aged 75 years or older, but this did not meet statis-
tical significance (log-rank p  0.10). On multivariate anal-
ysis, tumor stage and ECOG score were predictive of DSS,
whereas age was not (Table 2).
Patients Treated with Radical RT
The median age of the 248 patients in the RT cohort
was 76 years (range, 49–90 years), and 148 (60%) were aged
75 years or older. The diagnosis of NSCLC was made by
cytology or pathology in 229 cases (93%). Comparison of the
older and younger age groups revealed no significant differ-
ences in baseline characteristics (Table 1).
Most patients received hypofractionated RT regimens.
The most common dose-fractionation regimens were 55 Gy
in 20 fractions (49% of patients); 50 Gy in 20 fractions
(13%); 52.5 Gy in 20 fractions (6%); 60 Gy in 25 fractions
(4%); and 60 Gy in 30 fractions (4%). Four patients (1.6%)
received chemotherapy as part of their initial treatment. The
median normalized dose was 58 Gy in 2 Gy fractions.
There were 174 deaths in the RT cohort. The estimated
OS for RT patients at 2 years was 55% and at 5 years was
20%. A comparison of OS by age category is shown in Figure
2A. The OS rates for the elderly patients were 53% at 2 years
TABLE 1. Clinical Characteristics of 558 Patients with Stage I NSCLC, Treated with Radical Radiotherapy or Surgery, Stratified
by Treatment and Age
Variable
Surgery Radiation
Age <75 yr Age >75 yr
pa Comparing
Age Groups Age <75 yr Age >75 yr
pa Comparing
Age Groups
n 247 63 100 148
Age (median, range) 64 (20–74) 77 (75–86) 70 (49–74) 80 (75–90)
Sex (n, %) 0.09 0.90
Male 136 (55%) 27 (43%) 60 (60%) 87 (59%)
Female 111 (45%) 36 (57%) 40 (40%) 61 (41%)
Stage
IA 75 (30%) 20 (32%) 0.88 54 (54%) 74 (50%) 0.60
IB 172 (70%) 43 (68%) 46 (46%) 74 (50%)
Years of F/U (median, range) 2.9 (0.2–7.8) 2.8 (0.2–7.5) 0.88 2.1 (0.3–7.8) 1.9 (0.1–8.2) 0.87
ECOG (no, %)
0–1 151 (61%) 34 (54%) 0.49 51 (51%) 89 (60%) 0.30
2–3 31 (13%) 11 (18%) 18 (18%) 25 (17%)
Unknown 65 (26%) 18 (28%) 31 (31%) 34 (23%)
Driving time to nearest cancer center 2 h (n, %) 65 (26%) 18 (28%) 0.75 26 (26%) 34 (23%) 0.65
Histology (n, %) 0.11 0.42
Squamous 54 (21%) 23 (36%) 34 (34%) 47 (32%)
Large cell 21 (9%) 3 (5%) 5 (5%) 3 (2%)
Adenocarcinoma 145 (59%) 31 (49%) 18 (18%) 36 (24%)
NSCLC not otherwise specified/other 27 (11%) 6 (10%) 43 (43%) 62 (42%)
Mediastinoscopy (n, %) 129 (52%) 31 (49%) 0.68 19 (19%) 16 (11%) 0.09
Surgical procedure 0.21
Lobectomy 206 (83%) 56 (89%) N/A N/A
Pneumonectomy 19 (8%) 1 (1%) N/A N/A
Segmental resection 22 (9%) 6 (10%) N/A N/A
Radiotherapy dose (normalized to 2 Gy per fraction)
(median, range)
N/A N/A 58 (42–76) 58 (42–70) 0.132
Percentages are by column.
a t test, Fisher’s exact test, or 2, test as appropriate.
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
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and 23% at 5 years. There was no difference between the
older and younger groups in OS (log-rank p  0.88), and
there were no differences in OS by era of diagnosis (before
2003 versus 2003–2004 versus 2005 or later) in the whole RT
cohort (p  0.44) or in the elderly RT cohort (p  0.65). On
multivariate analysis (Table 2), factors predictive of OS were
FIGURE 1. Overall survival (A)
and disease-specific survival (B) for
310 patients with stage I non-small
cell lung cancer (NSCLC) treated
with surgery.
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tumor stage, sex, and dose, whereas age was not a significant
predictor.
Of the 174 deaths, 110 were due to lung cancer. The
estimated DSS at 2 years was 65% and at 5 years was 38%.
Kaplan-Meier estimates of DSS by age category are shown in
Figure 2B. There was no significant difference between the
older and younger groups in DSS (p 0.15). On multivariate
analysis (Table 2), the only factor predictive of DSS was
tumor stage, whereas RT dose approached significance and
age was not predictive.
DISCUSSION
We present a large study of 558 patients with stage I
lung cancer treated with curative intent, either with surgery or
radical RT, using prospectively collected data. To our knowl-
edge, this is the largest study addressing outcomes after both
radical surgery and RT in elderly stage I patients. Our
analysis is unique in capturing outcomes not only in patients
who were fit for surgery and underwent resection but also in
those who were unfit or declined surgery and proceeded to
radical RT instead. Although other studies have compared
outcomes between patients treated with surgery versus RT,
often the RT cohort included patients treated both radically
and palliatively,3 obscuring outcomes for radical RT.
Our data confirm that elderly patients are much less
likely to receive surgery than their younger counterparts—
only 30% of elderly patients in this study underwent
resection, compared with 71% of younger patients. How-
ever, when stratified by treatment, survival rates in the
elderly compare very favorably with their younger coun-
terparts who underwent the same therapies, and age was
not found to be predictive of survival outcomes on multi-
variate analysis. Although the Kaplan-Meier estimates of
DSS appeared to show trends toward inferior survival in
older patients, after controlling for other factors on multi-
variate analysis, these trends were no longer apparent.
Instead, the factors predictive of survival outcomes were
tumor stage and ECOG performance score for surgical
patients and tumor stage, dose, and sex for RT patients.
These findings indicate that if elderly patients are fit
enough to be referred and selected for radical treatment,
whether surgery or RT, then age does not contribute
significantly to survival outcomes.
Although outcomes for elderly patients with stage I
NSCLC are variable and strongly reflective of the baseline
patient population, the OS estimates in our study are consis-
tent with published data.21–23 Comparisons between outcomes
after RT and surgery are very difficult and were not done in
this study. Although the outcomes after RT seem to be
inferior to surgery, the exact difference in outcomes between
the two treatments cannot be easily ascertained. The two
treatment populations differ in baseline characteristics and
staging (pathologic versus clinical). Furthermore, the pres-
ence of “confounding by indication” is very difficult, if not
impossible, to address.24
Most series have indicated that long-term survival after
surgery or RT for early-stage lung cancer is not affected by
age,3,25 although some studies have found an inferior prog-
nosis with advanced age.26 The largest study, by Siegel et al.,
examined over 27,000 patients with stage I NSCLC from the
Surveillance, Epidemiology and End Results database. They
found that elderly patients who underwent resection have
similar survival to younger patients.3 The only previous
study, to our knowledge, that examined both surgery and
radical RT in elderly stage I patients was published in 1988
with 138 patients and reported that age did not affect post-
treatment survival.27
Although age does not seem to predict survival in
patients who receive radical treatment, age does have an
effect on whether patients are referred for treatment and
whether curative treatment is offered. Rates of referral and
RT utilization have been shown to decrease with age.7 As a
result, the patients included in studies examining outcomes
after radical treatments represent a selected group that likely
TABLE 2. Cox Multivariate Regression Analysis of Factors
Predictive of Overall Survival and Disease-Specific Survival
After Radical Treatment for Stage I Lung Cancer with
Surgery (OS and DSS) or Radiotherapy (OS and DSS)
Factor HR 95% CI p
Surgical patients
OS
Age (per year increase) 1.002 0.98–1.02 0.87
Tumor stage T2 (vs. T1) 1.76 1.04–2.95 0.034
ECOG score 1 (vs. 0–1) 1.06 1.01–1.13 0.03
Female sex 0.70 0.44–1.10 0.12
Squamous histology (vs.
nonsquamous)
0.76 0.43–1.36 0.32
Distance from cancer centre 2 h 0.97 0.57–1.63 0.89
DSS
Age 0.997 0.97–1.02 0.81
Tumor stage T2 1.96 1.01–3.78 0.045
ECOG score 1 1.06 1.01–1.12 0.03
Female sex 0.70 0.39–1.22 0.20
Squamous histology 1.05 0.55–1.99 0.89
Distance from cancer centre 2 h 1.08 0.57–2.03 0.82
Radiotherapy patients
OS
Age 1.01 0.99–1.03 0.43
Tumor stage T2 1.39 1.03–1.87 0.033
Normalized dose (per 1 Gy increase) 0.95 0.91–0.99 0.01
ECOG score 1 1.12 0.94–1.33 0.21
Female sex 0.73 0.54–0.99 0.044
Squamous histology 1.17 0.82–1.69 0.35
Distance from cancer centre 2 h 0.89 0.62–1.29 0.55
DSS
Age 1.01 0.99–1.04 0.27
Tumor stage T2 1.49 1.06–2.07 0.02
Normalized dose 0.96 0.91–1.003 0.06
ECOG score 1 1.06 0.87–1.31 0.56
Female sex 0.80 0.56–1.14 0.21
Squamous histology 1.21 0.78–1.92 0.30
Distance from cancer centre 2 h 0.89 0.59–1.34 0.58
OS, overall survival; DSS, disease-specific survival; ECOG, Eastern Cooperative
Oncology Group; HR, hazard ratio; CI, confidence interval.
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FIGURE 2. Overall survival (A)
and disease-specific survival (B) for
248 patients with stage I non-small
cell lung cancer (NSCLC) treated
with radical radiotherapy (RT).
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differs from the baseline population of elderly patients. Our
data did not allow us to draw conclusions on elderly patients
with stage I NSCLC who were never referred for treatment.
Treatment options for elderly patients with stage I
NSCLC have evolved over the past 10 years, and newly
diagnosed patients may have more options available than the
patients in this cohort. Minimally invasive surgery using
video-assisted thoracic surgery decreases operative morbidity
and can allow for resection in elderly patients who would
otherwise be unfit for surgery.28 Fitness for surgery and
operative mortality risks can be assessed preoperatively using
validated instruments.29 There has been a change in the RT
treatment paradigm, with the delivery of large ablative doses
using stereotactic body radiation therapy. Stereotactic
body radiation therapy has been shown to achieve high
rates of local control in elderly patients, with a good
side-effect profile.30
The findings of this study should be considered in the
context of its strengths and limitations. As is common with
the use of large administrative databases, data were not
recorded for all variables of interest, particularly comorbidi-
ties, weight loss at presentation, toxicity, and quality of life.
Patients with stage I disease who received palliative RT or no
treatment are not included, and these patients may be more
likely to be elderly.7 The surgical data is not population-
based, and elderly patients may have been less likely to be
referred to a BCCA surgeon or referred after surgery for
consideration of adjuvant therapy. Positron emission tomog-
raphy scanning was not widely available in BC until 2004,
and therefore most patients in this cohort did not undergo
positron emission tomography scans.
In conclusion, our study shows that survival outcomes
for elderly patients after radical treatment for stage I NSCLC
are similar to those of younger patients, whether treated with
surgery or RT. In making decisions regarding treatment for
elderly patients, oncologists should consider the individual
characteristics of each patient, and elderly patients who are
sufficiently fit should be considered for curative treatments.
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